The U.S. Centers for Disease Control and Prevention (CDC) awarded a $60,250.00 firm fixed price purchase order contract to Qiagen, LLC, a division of the parent company Qiagen N.V. The contract has an ultimate completion date of September 28, 2024 and was awarded on September 29, 2023. Qiagen is an international provider of sample and assay technologies for molecular diagnostics, applied testing, pharmaceuticals, and academics. This contract does not have a set-aside designation. Qiagen has...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a $55,000.00 firm fixed price purchase order contract to Qiagen, LLC, a division of Qiagen N.V., an international provider of sample and assay technologies for molecular diagnostics, applied testing, pharma, and academics. This contract has a completion date of May 21, 2024. Qiagen is a foreign-owned, for-profit manufacturer that has provided a range of products and services to support federal...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a firm fixed-price purchase order to Qiagen, LLC, a division of Qiagen N.V., for the acquisition of QIAGEN equipment and reagents. The contract, valued at $134,538.38, does not have a set-aside designation. Qiagen N.V. is an international provider of sample and assay technologies for molecular diagnostics, applied testing, pharma, and academic research. The company has a history of supporting federal...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a firm-fixed-price purchase order to Qiagen, LLC for a PYROMARK Q48 SYSTEM with a completion date of July 20, 2019 and a potential value of $139,884.28. Qiagen, LLC is a division of Qiagen N.V., an international provider of sample and assay technologies. Qiagen has provided a range of products and services, including DNA/RNA extraction kits, next-generation sequencing, and precision medicine...
This is a $14,288 firm fixed-price purchase order awarded by the Centers for Disease Control and Prevention (CDC) to Qiagen, LLC, a division of Qiagen N.V. The contract has a period of performance from April 1, 2025 to March 31, 2026 for Qiagen to provide laboratory services under the IP0023 Statement of Work. No set-aside designation was used. Qiagen is an international provider of sample and assay technologies for molecular diagnostics, applied testing, and other applications. The company...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a $57,348.26 firm fixed-price purchase order contract to Qiagen, LLC, a division of the international provider Qiagen N.V., for QIACUITY equipment and maintenance services. This contract does not have a set-aside designation. Qiagen has a history of providing products and services, such as DNA/RNA extraction kits, next-generation sequencing, and bioinformatics software, to support federal agencies'...
This firm fixed-price purchase order was awarded by the Centers for Disease Control and Prevention (CDC) to Qiagen, LLC, a division of the international provider of sample and assay technologies Qiagen N.V. The $148,000.00 contract is for the delivery of products and services to support the CDC's biomedical research, public health, and healthcare programs. This includes DNA/RNA extraction kits, next-generation sequencing, digital PCR systems, sample preparation equipment, bioinformatics...
This is a $145,237 firm fixed-price purchase order awarded by the Centers for Disease Control and Prevention (CDC) to Qiagen, LLC, a subsidiary of the multinational biotechnology company Qiagen N.V. The contract is for "other functions" and does not have a set-aside designation. Qiagen is a provider of sample and assay technologies for molecular diagnostics, applied testing, pharma, and academic research. Under this award, Qiagen is likely providing products and services to support the...
This is a $148,157.70 firm fixed-price purchase order contract awarded by the Department of Health and Human Services Centers for Disease Control and Prevention to Qiagen, LLC, a division of the international biotechnology company Qiagen N.V. The contract is for other unspecified functions and does not have a set-aside designation. Qiagen has provided a range of products and services to support federal agencies' biomedical research, public health, law enforcement, and healthcare programs under...
This firm-fixed-price purchase order was awarded by the Centers for Disease Control and Prevention (CDC) to Qiagen, LLC, a subsidiary of the multinational biotechnology company Qiagen N.V. The $64,817.75 contract provides planned maintenance services for QIAGEN equipment, with a period of performance through March 31, 2024. Qiagen is a major supplier of molecular diagnostics products and services to federal agencies, including the Department of Health and Human Services, Department of Veterans...